Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TLPO Vaccine in Solid Tumor Malignancies
NCT06175221Phase 2Terminated
- Sponsor
- Elios Therapeutics
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TLPO vaccine in solid tumor, sponsored by Elios Therapeutics. Started Nov 2023; status: terminated.
02
Drugs
TLPO vaccine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06175221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175221.